Achieve Life Sciences (ACHV) Convertible Debt (2021 - 2026)

Achieve Life Sciences (ACHV) has 6 years of Convertible Debt data on file, last reported at $9.3 million in Q1 2026.

• Quarterly Convertible Debt rose 7.68% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 7.68% YoY) and the FY2025 annual result came in at $11.2 million, up 13.7% from the prior year.
• Convertible Debt retreated to $9.3 million in Q1 2026, from $11.2 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $16.2 million in Q3 2023 to a low of $8.7 million in Q1 2025.
• A 5-year average of $11.8 million and a median of $9.8 million in 2024 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2024 — Convertible Debt tumbled 44.03% — and 2025, when it gained 13.7%.
• Tracing ACHV's Convertible Debt over 5 years: stood at $15.8 million in 2022, then advanced by 2.74% to $16.2 million in 2023, then plunged by 39.26% to $9.8 million in 2024, then grew by 13.7% to $11.2 million in 2025, then slipped by 16.66% to $9.3 million in 2026.
• The last three Convertible Debt figures came in at $9.3 million (Q1 2026), $11.2 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.